Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

100 ta ish

Ish: Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

  1. Cancer stem cells: advances in knowledge and implications for cancer therapy

    Xianjing Chu, Wentao Tian, Jiaoyang Ning +7

    Maqola20248 iqtibos
    ABI

  2. Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence

    Beatrice Aramini, Valentina Masciale, Giulia Grisendi +8

    Sharh maqola20226 iqtibos
    ABI

  3. Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions

    Kaveh Hadiloo, Parsa Mostanadi, Ali Asadzadeh +2

    Sharh maqola20256 iqtibos
    ABI

  4. Targeting cancer stem cell pathways for cancer therapy

    Liqun Yang, Pengfei Shi, Gaichao Zhao +8

    Sharh maqolaOchiq kirish20205 iqtibos
    ABI

  5. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

    Xinyi Xiao, Shengkang Huang, Sifei Chen +4

    Sharh maqolaOchiq kirish20215 iqtibos
    ABI

  6. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

    Lei Peng, Giacomo Sferruzza, Luojia Yang +2

    Sharh maqolaOchiq kirish20245 iqtibos
    ABI

  7. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

    Gh. Rasool Bhat, Itty Sethi, Hana Q. Sadida +14

    Sharh maqola20245 iqtibos
    ABI

  8. The clinical landscape of CAR NK cells

    Lasse Vedel Jørgensen, Emil Birch Christensen, Mike Bogetofte Barnkob +1

    Sharh maqola20255 iqtibos
    ABI

  9. The tumor microenvironment’s role in the response to immune checkpoint blockade

    Konstantinos Aliazis, Anthos Christofides, Rushil Shah +4

    Sharh maqolaOchiq kirish20254 iqtibos
    ABI

  10. Long-term outcomes following CAR T cell therapy: what we know so far

    Kathryn M. Cappell, James N. Kochenderfer

    Sharh maqolaOchiq kirish20233 iqtibos
    ABI

  11. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners

    Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz +7

    Sharh maqolaOchiq kirish20213 iqtibos
    ABI

  12. Cancer Stem Cell Plasticity Drives Therapeutic Resistance

    Mary R. Doherty, Jacob Smigiel, Damian J. Junk +1

    Sharh maqola20163 iqtibos
    ABI

  13. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

    Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8

    Sharh maqola20253 iqtibos
    ABI

  14. The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

    Maximilian Haist, Henner Stege, Stephan Grabbe +1

    Sharh maqola20213 iqtibos
    ABI

  15. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

    Yongshuai Jiang, Ming Chen, Hong Nie +1

    Sharh maqolaOchiq kirish20192 iqtibos
    ABI

  16. Microenvironmental regulation of therapeutic response in cancer

    Florian Klemm, Johanna A. Joyce

    Sharh maqola20142 iqtibos
    ABI

  17. The NF-κB Pathway and Cancer Stem Cells

    Amanda L. Rinkenbaugh, Albert S. Baldwin

    Sharh maqola20162 iqtibos
    ABI

  18. Targeting cancer stem cells in drug discovery: Current state and future perspectives

    Fangyu Du, Qifan Zhou, Wenjiao Sun +1

    Sharh maqola20192 iqtibos
    ABI

  19. The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells

    Deobrat Dixit, Briana C. Prager, Ryan C. Gimple +16

    Maqola20202 iqtibos
    ABI

  20. Cellular and molecular mechanisms of plasticity in cancer

    Stefan Torborg, Zhuxuan Li, Jason E. Chan +1

    Sharh maqola20222 iqtibos
    ABI

  21. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

    Vinicio Melo, Edwin Bremer, John D. Martin

    Sharh maqola20222 iqtibos
    ABI

  22. Metabolic challenges and interventions in CAR T cell therapy

    Jhan-Jie Peng, Limei Wang, Zhiyu Li +2

    Sharh maqola20232 iqtibos
    ABI

  23. CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance

    Diane Coursier, Fernando Calvo

    Sharh maqola20242 iqtibos
    ABI

  24. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function

    Matthew Bell, Stephen Gottschalk

    Sharh maqola20212 iqtibos
    ABI

  25. Improving CAR T-Cell Persistence

    Violena Pietrobon, Lauren A. Todd, Anghsumala Goswami +3

    Sharh maqola20212 iqtibos
    ABI